Education
About Us
Working with TipRanks
Follow Us
Agios Pharmaceuticals (AGIO)
:AGIO
AGIO Stock Chart & Stats
$42.65
-$0.03(-0.09%)
At close: 4:00 PM EST
$42.65
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$23.42 - $62.58
Previous CloseN/A
Volume212.48K
Average Volume (3M)591.96K
Market Cap
$2.48B
Enterprise Value$1.04B
Total Cash (Recent Filing)$938.94M
Total Debt (Recent Filing)$48.76M
Price to Earnings (P/E)3.9
Beta1.69
Next Earnings
Oct 30, 2025EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding58,101,517
10 Day Avg. Volume567,278
30 Day Avg. Volume591,955
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue25.36
Enterprise Value/Gross Profit29.80
Enterprise Value/Ebitda-2.34
Forecast
1Y Price Target
$51.33Price Target Upside20.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Approval And Market PotentialA positive CHMP opinion from the EMA for mitapivat in thalassemia boosts confidence in its market potential.
Global ExpansionPyrukynd was approved in Saudi Arabia to treat all types of thalassemia, which increases confidence in broader US/EU approval.
Strategic PartnershipsThe European Commission approval, coupled with a commercialization and distribution partnership with Avanzanite Bioscience, establishes a clear, capital-efficient strategy for realizing international sales.
Bears Say
Market UncertaintyPayers may also consider restricting access until they can better understand the implications and management of the REMS.
Regulatory ChallengesThe inclusion of a black box warning and a stated REMS request poses a risk for the launch of mitapivat.
Stock VolatilityThe extension of the PDUFA date was due to concerns about hepatocellular injury, leading to a decrease in stock price.
Agios Pharma News
AGIO FAQ
What was Agios Pharmaceuticals’s price range in the past 12 months?
Agios Pharmaceuticals lowest stock price was $23.41 and its highest was $62.58 in the past 12 months.
What is Agios Pharmaceuticals’s market cap?
Agios Pharmaceuticals’s market cap is $2.48B.
When is Agios Pharmaceuticals’s upcoming earnings report date?
Agios Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 8 days.
How were Agios Pharmaceuticals’s earnings last quarter?
Agios Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$1.807 by -$0.123.
Is Agios Pharmaceuticals overvalued?
According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued.
Does Agios Pharmaceuticals pay dividends?
Agios Pharmaceuticals does not currently pay dividends.
What is Agios Pharmaceuticals’s EPS estimate?
Agios Pharmaceuticals’s EPS estimate is -1.9.
How many shares outstanding does Agios Pharmaceuticals have?
Agios Pharmaceuticals has 58,101,517 shares outstanding.
What happened to Agios Pharmaceuticals’s price movement after its last earnings report?
Agios Pharmaceuticals reported an EPS of -$1.93 in its last earnings report, missing expectations of -$1.807. Following the earnings report the stock price went down -0.852%.
Which hedge fund is a major shareholder of Agios Pharmaceuticals?
Currently, no hedge funds are holding shares in AGIO
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.33 (20.35% Upside)
$51.33 (20.35% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 400.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $315.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 85.2%
Last 30 Days ▲ 85.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.26%
12-Months-Change
Fundamentals
Return on Equity
64.05%
Trailing 12-Months
Asset Growth
90.31%
Trailing 12-Months
Company Description
Agios Pharmaceuticals
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare diseases, particularly cancer and genetic metabolic disorders. The company specializes in small molecule drugs that target specific metabolic pathways, with a strong emphasis on advancing treatments that address unmet medical needs. Agios's core products include its lead drug, ivosidenib, which is designed for the treatment of acute myeloid leukemia (AML), and other pipeline candidates aimed at various rare diseases.
AGIO Company Deck
AGIO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with strong revenue growth for PYRUKYND, advancements in regulatory approvals, and strategic partnerships to expand global reach. However, there were also concerns about revenue variability, increased expenses, and challenges in market expansion, which could temper expectations. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$51.33
▲(20.35% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
0.87% Insiders
26.60% Mutual Funds
0.20% Other Institutional Investors
55.02% Public Companies and
Individual Investors